What can your synchrotron do for you?

Life Science Nord event reveals how pharmaceutical companies use synchrotrons for their research.

By Rosemary Wilson


Resourceful alumni

Two EMBL alumni, each developing community-led tools to support life science research

By Chloe Cross


Forty things that make EMBL – Part 2

As the Lab turns 40, staff and alumni share 40 things that make EMBL, EMBL

By Adam Gristwood

Lab Matters

On target

A new EMBL-EBI biomedical initiative works to determine the best target proteins for new drugs.

By Mary Todd Bergman

Lab Matters

EMBL coordinates new Marie Curie Research Training Network “Chromatin Plasticity”

The European Commission has awarded 3.7 Million Euro under the European Union Framework 6 Programme over the next four years to a new Marie Curie Research Training Network, coordinated by Dr. Andreas Ladurner at the European Molecular Biology Laboratory (EMBL). The long molecules of DNA that carry…

By Guest author(s)

Lab Matters

EMBL scientists found start-up company to develop anti-cancer drugs

Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new…

By Guest author(s)

Lab Matters


Read the latest Issues of our magazine - EMBLetc.

Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.

EMBLetc. archive